LATEST UPDATES » Vol 24, No. 08, August 2020 – Unravelling the Mysteries of the Human Brain       » Reducing Blood Sugar with Tea Leaves in Type 2 Diabetic Rats       » Generating Clean Water from Solar-Powered Technology       » COVID-19 Diagnostic Kits: The Singapore Story       » Fighting for Sustainability: One Shrimp at a Time       » Creating Robotic Systems with Vision and Touch Sensors      
Vol 24, No. 07, July 2020   |   Issue PDF view/purchase
Development of Technology to Carry Therapeutic Genes to Target Cancer Cells
Shinshu University and Toshiba have formulated a tumour-tropic liposome technology for transporting therapeutic genes into cancer cells.

Toshiba Corporation and a team led by Professor Yozo Nakazawa at the Department of Paediatrics, Shinshu University, have together developed a “tumour-tropic liposome technology” for cancer gene therapy. The technology uses unique, nano-sized biodegradable liposomes developed by Toshiba to accurately and efficiently deliver therapeutic genes to targeted cancer cells, and achieves safer gene delivery than viruses used as carriers.

The tumour-tropic liposome developed by Toshiba can deliver therapeutic genes selectively to tumour cells, not normal cells. Shinshu university and Toshiba have demonstrated that the tumour-tropic liposome can deliver the therapeutic gene to T-cell leukaemia cells and achieve a 30-fold increase in uptake and 400-fold increase in gene expression than normal T-cells. The technology is expected to reduce burdens on patients during treatment, and offers the potential to develop new treatments for other cancers.

The technology was presented by Shinshu University and Toshiba at the annual American Society for Gene & Cell Therapy held on 12 May 2020.

In cancer gene therapy, it involves the insertion of therapeutic genes into target cells to repair cell function. While this might offer a promising way to treat cancers, methods of gene therapy have yet to be concrete with many barriers still to overcome.

Transporting the therapeutic genes into a target cell is one of these barriers. Current approaches often achieve this by using a virus as the carrier. However, it brings with concerns for the risk of infection and cell tropism.

Collaboration between Shinshu University and Toshiba have reaped results of utilising biodegradable liposomes as non-virus carriers of therapeutic genes. This led to the development of tumour-tropic liposomes that are able to safely and effectively deliver therapeutic genes to targeted cancer cells.

Toshiba has applied its know-how in materials technology to the design of liposomes with lipids that degrade naturally in cells, as their major component. Toshiba will continue to contribute its specialized capabilities in materials science to the collaboration with Shinshu University, in support of further enhancing the delivery and application of cancer-directed liposomes and promoting the widespread use of gene therapy.


news Proteona Honoured with "one to watch" Prize in the Inaugural Spinoff Prize by Nature Research and Merck Grou
news Twist Bioscience and Proteona Join Hands to Protect Immunocompromised Patients from COVID-19 Infection
news Meeting Demand for Respiratory Ventilators Amid COVID-19 Pandemic
news Innovation in Healthcare: IOT-Enabled Tele-Ventilators to Fight Against the COVID-19 Pandemic

About Us
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2020 World Scientific Publishing Co Pte Ltd  •  Privacy Policy